Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19647445 | 0.87 | F10 (0.62) | F10PTGS2 | |
| SCHEMBL1677899 | 0.87 | F10 (0.60) | F10PTGS2 | |
| SCHEMBL28407706 | 0.87 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL19647435 | 0.87 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL118728 | 0.85 | F10 (0.58) | F10PTGS2 | |
| SCHEMBL1679321 | 0.83 | F10 (0.65) | F10PTGS2 | |
| SCHEMBL6453826 | 0.82 | F10 (0.64) | F10PTGS2 | |
| SCHEMBL25207144 | 0.82 | GAA (0.56) | F10PTGS2 | |
| SCHEMBL2639314 | 0.82 | F10 (0.62) | F10PTGS2 | |
| SCHEMBL1380646 | 0.81 | F10 (0.62) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014170908-A1 | PROCESS FOR PREPARATION OF OXAZOLIDINONE DERIVATIVES | NOSCH LABS PRIVATE LIMITED (IN) | 2014-10-23 | — | — | WO | disclosed |
| US-20140128601-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | INTERQUIM, S.A. (ES) | 2014-05-08 | — | — | US | disclosed |
| EP-2710001-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | Interquim, S.A. (ES) | 2014-03-26 | — | — | EP | disclosed |
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | disclosed |
| WO-2012159992-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | INTERQUIM, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
| EP-2424847-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Apotex Pharmachem Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010124385-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128601-A1 | PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF | TFPI, CYP2C9, CYP2C19 | F10 20/4885PTGS2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.